Skip to main content
Top
Published in: Heart Failure Reviews 4-5/2012

01-09-2012

Pharmacotherapy of heart failure in the elderly: adverse events

Author: Michael W. Rich

Published in: Heart Failure Reviews | Issue 4-5/2012

Login to get access

Abstract

Aging is associated with numerous alterations in body composition and organ function that result in substantial changes in the absorption, distribution, metabolism, and elimination of virtually all drugs. In addition, older patients with heart failure (HF) almost invariably have multiple coexisting medical conditions for which they are receiving medications. This article reviews common adverse drug effects and drug interactions associated with HF therapy in older patients and discusses strategies for reducing the risk of adverse drug events. In order to minimize these risks, it is essential that clinicians avoid prescribing unnecessary medications, adjust medication dosages to optimally balance benefits and side effects, and remain ever vigilant to the potential for medications to cause or contribute to clinically important adverse events and impaired quality of life. In treating older HF patients, the oft-cited dictum “start low, go slow” clearly applies. Despite the inherent challenges, with careful management and close follow-up, most older HF patients can be successfully treated through the judicious use of guideline-recommended HF therapies.
Literature
1.
go back to reference Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9:384–398PubMedCrossRef Stegemann S, Ecker F, Maio M et al (2010) Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev 9:384–398PubMedCrossRef
2.
3.
go back to reference Braunstein JB, Anderson GF, Gerstenblith G et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233PubMedCrossRef Braunstein JB, Anderson GF, Gerstenblith G et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233PubMedCrossRef
4.
go back to reference Rich MW (2005) Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Card 14:134–141CrossRef Rich MW (2005) Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Card 14:134–141CrossRef
5.
go back to reference Stevens LA, Levey AS (2005) Chronic kidney disease in the elderly—how to assess risk. N Engl J Med 352:2122–2124PubMedCrossRef Stevens LA, Levey AS (2005) Chronic kidney disease in the elderly—how to assess risk. N Engl J Med 352:2122–2124PubMedCrossRef
6.
go back to reference Hanlon JT, Aspinall SL, Semla TP et al (2009) Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 57:335–340PubMedCrossRef Hanlon JT, Aspinall SL, Semla TP et al (2009) Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 57:335–340PubMedCrossRef
7.
go back to reference Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG (2008) The aging kidney. Kidney Internat 74(6):710–720CrossRef Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG (2008) The aging kidney. Kidney Internat 74(6):710–720CrossRef
8.
go back to reference Kenney WL, Chiu P (2001) Influence of age on thirst and fluid intake. Med Sci Sports Exerc 33:1524–1532PubMedCrossRef Kenney WL, Chiu P (2001) Influence of age on thirst and fluid intake. Med Sci Sports Exerc 33:1524–1532PubMedCrossRef
9.
go back to reference Shem S (1979) House of God. Random House, Inc, New York Shem S (1979) House of God. Random House, Inc, New York
10.
go back to reference Steinman MA, Hanlon JT (2010) Managing medications in clinically complex elders. “There’s got to be a happy medium”. JAMA 304:1592–1601PubMedCrossRef Steinman MA, Hanlon JT (2010) Managing medications in clinically complex elders. “There’s got to be a happy medium”. JAMA 304:1592–1601PubMedCrossRef
11.
go back to reference Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752PubMedCrossRef Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752PubMedCrossRef
12.
go back to reference Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587PubMedCrossRef Pitt B, Poole-Wilson PA, Segal R et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587PubMedCrossRef
13.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
14.
go back to reference Levey AS, Bosch JP, Lewis JB (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predication equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed Levey AS, Bosch JP, Lewis JB (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predication equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed
15.
go back to reference Massie BM, Armtrong PW, Cleland JG et al (2001) Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 161:165–171PubMedCrossRef Massie BM, Armtrong PW, Cleland JG et al (2001) Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 161:165–171PubMedCrossRef
16.
go back to reference Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318PubMed Packer M, Poole-Wilson PA, Armstrong PW et al (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312–2318PubMed
17.
go back to reference Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551PubMedCrossRef Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543–551PubMedCrossRef
18.
go back to reference Tamirisa KP, Aaronson KD, Koelling TM (2004) Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148:971–978PubMedCrossRef Tamirisa KP, Aaronson KD, Koelling TM (2004) Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148:971–978PubMedCrossRef
20.
go back to reference Hunt SA, Abraham WT, Chin MH et al (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation 119:e391–e479PubMedCrossRef Hunt SA, Abraham WT, Chin MH et al (2009) 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation 119:e391–e479PubMedCrossRef
21.
go back to reference Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107:346–354PubMedCrossRef Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 107:346–354PubMedCrossRef
22.
go back to reference Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107:490–497PubMedCrossRef Lakatta EG (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107:490–497PubMedCrossRef
23.
go back to reference Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Ageing 17:353–362CrossRef Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Ageing 17:353–362CrossRef
24.
go back to reference Ahmed A, Rich MW, Love TE et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:178–186PubMedCrossRef Ahmed A, Rich MW, Love TE et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:178–186PubMedCrossRef
25.
go back to reference Rich MW, McSherry F, Williford WO, Yusuf S (2001) Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38:806–813PubMedCrossRef Rich MW, McSherry F, Williford WO, Yusuf S (2001) Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 38:806–813PubMedCrossRef
26.
go back to reference Weil J, Sen Gupta R, Herfarth H (2004) Nonocclusive mesenteric ischemia induced by digitalis. Int J Colorectal Dis 19:277–280PubMedCrossRef Weil J, Sen Gupta R, Herfarth H (2004) Nonocclusive mesenteric ischemia induced by digitalis. Int J Colorectal Dis 19:277–280PubMedCrossRef
27.
go back to reference Schaefer DC, Cheskin LJ (1998) Constipation in the elderly. Am Fam Phys 58:907–914 Schaefer DC, Cheskin LJ (1998) Constipation in the elderly. Am Fam Phys 58:907–914
28.
go back to reference Kitzman DW, Gardin JM, Gottdiener JS et al (2001) Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 87:413–419PubMedCrossRef Kitzman DW, Gardin JM, Gottdiener JS et al (2001) Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 87:413–419PubMedCrossRef
29.
go back to reference Heart Failure Society of America (2010) Comprehensive heart failure practice guidelines. Heart failure in patients with preserved ejection fraction. J Cardiac Fail 16:e73–e97CrossRef Heart Failure Society of America (2010) Comprehensive heart failure practice guidelines. Heart failure in patients with preserved ejection fraction. J Cardiac Fail 16:e73–e97CrossRef
30.
go back to reference Tsang TS, Gersh BJ, Appleton CP et al (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40:1636–1644PubMedCrossRef Tsang TS, Gersh BJ, Appleton CP et al (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40:1636–1644PubMedCrossRef
31.
go back to reference Seymour RM, Routledge PA (1998) Important drug–drug interactions in the elderly. Drugs Ageing 12:485–494CrossRef Seymour RM, Routledge PA (1998) Important drug–drug interactions in the elderly. Drugs Ageing 12:485–494CrossRef
32.
go back to reference Whelton A (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106:13S–24SPubMedCrossRef Whelton A (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106:13S–24SPubMedCrossRef
33.
go back to reference Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Int Med 160:777–784CrossRef Page J, Henry D (2000) Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Int Med 160:777–784CrossRef
34.
go back to reference Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322PubMedCrossRef Vassallo P, Trohman RG (2007) Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 298:1312–1322PubMedCrossRef
35.
go back to reference Shirolkar SC, Fiuzat M, Becker RC (2010) Dronedarone and vitamin K antagonists: a review of drug–drug interactions. Am Heart J 160:577–582PubMedCrossRef Shirolkar SC, Fiuzat M, Becker RC (2010) Dronedarone and vitamin K antagonists: a review of drug–drug interactions. Am Heart J 160:577–582PubMedCrossRef
36.
go back to reference Obialo CI, Ofili EO, Mirza T (2002) Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 90:663–665PubMedCrossRef Obialo CI, Ofili EO, Mirza T (2002) Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol 90:663–665PubMedCrossRef
37.
go back to reference Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878PubMedCrossRef Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–2878PubMedCrossRef
38.
go back to reference Cohen PA, Ernst E (2010) Safety of herbal supplements: a guide for cardiologists. Cardiovasc Therapeut 28:246–253CrossRef Cohen PA, Ernst E (2010) Safety of herbal supplements: a guide for cardiologists. Cardiovasc Therapeut 28:246–253CrossRef
39.
go back to reference Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A (2011) Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Cardiac Fail 17:217–223CrossRef Gastelurrutia P, Benrimoj SI, Espejo J, Tuneu L, Mangues MA, Bayes-Genis A (2011) Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: impact of a pharmacist in a multidisciplinary HF clinic. J Cardiac Fail 17:217–223CrossRef
40.
go back to reference Fulmer TT, Feldman PH, Kim TS et al (1999) An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nursing 25:6–14 Fulmer TT, Feldman PH, Kim TS et al (1999) An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nursing 25:6–14
41.
go back to reference Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part 1: aging arteries: a “set up” for vascular disease. Circulation 107:139–146PubMedCrossRef Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part 1: aging arteries: a “set up” for vascular disease. Circulation 107:139–146PubMedCrossRef
42.
go back to reference Gupta V, Lipsitz LA (2007) Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 120:841–847PubMedCrossRef Gupta V, Lipsitz LA (2007) Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 120:841–847PubMedCrossRef
43.
go back to reference Poluri A, Mores J, Cook DB, Findley TW, Cristian A (2005) Fatigue in the elderly population. Phys Med Rehab Clin North Am 16:91–108CrossRef Poluri A, Mores J, Cook DB, Findley TW, Cristian A (2005) Fatigue in the elderly population. Phys Med Rehab Clin North Am 16:91–108CrossRef
44.
45.
46.
go back to reference Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U (2007) Hypertension and cognitive function in the elderly. Am J Therapeut 14:533–554CrossRef Cherubini A, Lowenthal DT, Paran E, Mecocci P, Williams LS, Senin U (2007) Hypertension and cognitive function in the elderly. Am J Therapeut 14:533–554CrossRef
Metadata
Title
Pharmacotherapy of heart failure in the elderly: adverse events
Author
Michael W. Rich
Publication date
01-09-2012
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 4-5/2012
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-011-9263-1

Other articles of this Issue 4-5/2012

Heart Failure Reviews 4-5/2012 Go to the issue